Literature DB >> 28604413

Single-chain factor XII: a new form of activated factor XII.

Ivan Ivanov1, Anton Matafonov, David Gailani.   

Abstract

PURPOSE OF REVIEW: Exposure of blood to foreign surfaces induces reciprocal conversion of the plasma proteins factor XII (fXII) and plasma prekallikrein (PPK) to the proteases α-fXIIa and α-kallikrein. This process, called contact activation, has a range of effects on host defence mechanisms, including promoting coagulation. The nature of the triggering mechanism for contact activation is debated. One hypothesis predicts that fXII has protease activity, either intrinsically or upon surface-binding, that initiates contact activation. We tested this by assessing the proteolytic activity of a recombinant fXII variant that cannot be converted to α-fXIIa. RECENT
FINDINGS: The proteolytic activity of fXII-T (for 'triple' mutant), a variant with alanine substitutions for arginine at activation cleavage sites (Arg334, Arg344, and Arg353) was tested with known α-fXIIa substrates. FXII-T activates PPK in solution, and the reaction is enhanced by polyphosphate, an inducer of contact activation released from platelets. In the presence of polyphosphate, fXII-T converts fXII to α-fXIIa, and also converts the coagulation protein factor XI to its active form.
SUMMARY: The findings support the hypothesis that contact activation is initiated through activity intrinsic to single-chain fXII, and indicate that preexisting α-fXIIa is not required for induction of contact activation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28604413      PMCID: PMC5762122          DOI: 10.1097/MOH.0000000000000363

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  77 in total

1.  Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation.

Authors:  Rainer Friedrich; Peter Panizzi; Pablo Fuentes-Prior; Klaus Richter; Ingrid Verhamme; Patricia J Anderson; Shun-Ichiro Kawabata; Robert Huber; Wolfram Bode; Paul E Bock
Journal:  Nature       Date:  2003-10-02       Impact factor: 49.962

2.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

3.  Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa.

Authors:  D E Cool; C J Edgell; G V Louie; M J Zoller; G D Brayer; R T MacGillivray
Journal:  J Biol Chem       Date:  1985-11-05       Impact factor: 5.157

Review 4.  Medical device-induced thrombosis: what causes it and how can we prevent it?

Authors:  I H Jaffer; J C Fredenburgh; J Hirsh; J I Weitz
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 5.  Step-by-step evolution of vertebrate blood coagulation.

Authors:  R F Doolittle
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2009-08-10

6.  Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.

Authors:  Ivan Ivanov; Ruhama Shakhawat; Mao-Fu Sun; S Kent Dickeson; Cristina Puy; Owen J T McCarty; Andras Gruber; Anton Matafonov; David Gailani
Journal:  Thromb Haemost       Date:  2017-01-26       Impact factor: 5.249

Review 7.  Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.

Authors:  Elizabeth M Van Cott; A Joshua Roberts; William E Dager
Journal:  Semin Thromb Hemost       Date:  2017-01-04       Impact factor: 4.180

8.  A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Authors:  Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani
Journal:  Thromb Res       Date:  2016-02-18       Impact factor: 3.944

9.  Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

Authors:  Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

10.  Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.

Authors:  Linda Labberton; Ellinor Kenne; Andy T Long; Katrin F Nickel; Antonio Di Gennaro; Rachel A Rigg; James S Hernandez; Lynn Butler; Coen Maas; Evi X Stavrou; Thomas Renné
Journal:  Nat Commun       Date:  2016-09-06       Impact factor: 14.919

View more
  8 in total

1.  Protease activity in single-chain prekallikrein.

Authors:  Ivan Ivanov; Ingrid M Verhamme; Mao-Fu Sun; Bassem Mohammed; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Kusumam Joseph; Allen P Kaplan; David Gailani
Journal:  Blood       Date:  2020-02-20       Impact factor: 25.476

2.  A non-circulating pool of factor XI associated with glycosaminoglycans in mice.

Authors:  Bassem M Mohammed; Qiufang Cheng; Anton Matafonov; Ingrid M Verhamme; Jonas Emsley; Keith R McCrae; Owen J T McCarty; Andras Gruber; David Gailani
Journal:  J Thromb Haemost       Date:  2019-06-17       Impact factor: 16.036

3.  A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.

Authors:  Andrew McKenzie; Anthony Roberts; Sourabh Malandkar; Henrike Feuersenger; Con Panousis; Dipti Pawaskar
Journal:  Clin Transl Sci       Date:  2021-12-03       Impact factor: 4.689

4.  Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains.

Authors:  Aleksandr Shamanaev; Ivan Ivanov; Mao-Fu Sun; Maxim Litvak; Priyanka Srivastava; Bassem M Mohammed; Rabia Shaban; Ashoka Maddur; Ingrid M Verhamme; Owen J T McCarty; Ruby H P Law; David Gailani
Journal:  Blood Adv       Date:  2022-05-24

Review 5.  Proteolytic activity of contact factor zymogens.

Authors:  Aleksandr Shamanaev; Jonas Emsley; David Gailani
Journal:  J Thromb Haemost       Date:  2020-12-07       Impact factor: 5.824

6.  A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.

Authors:  Ivan Ivanov; Anton Matafonov; Mao-Fu Sun; Bassem M Mohammed; Qiufang Cheng; S Kent Dickeson; Suman Kundu; Ingrid M Verhamme; Andras Gruber; Keith McCrae; David Gailani
Journal:  Blood       Date:  2018-12-27       Impact factor: 25.476

Review 7.  Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis.

Authors:  Lysann Bender; Henri Weidmann; Stefan Rose-John; Thomas Renné; Andy T Long
Journal:  Front Immunol       Date:  2017-09-15       Impact factor: 7.561

8.  Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates.

Authors:  Michael Wallisch; Christina U Lorentz; Hari H S Lakshmanan; Jennifer Johnson; Marschelle R Carris; Cristina Puy; David Gailani; Monica T Hinds; Owen J T McCarty; András Gruber; Erik I Tucker
Journal:  Res Pract Thromb Haemost       Date:  2020-02-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.